Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05695248 · ClinicalTrials.gov registry record · Phase 1
A Study of STAR-0215 in Participants With Hereditary Angioedema
A Phase 1 study of Hereditary Angioedema, sponsored by Astria Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT05695248: Completed Phase 1 study of Hereditary Angioedema, sponsored by Astria Therapeutics.
NCT05695248 is a Phase 1 study of Hereditary Angioedema that has completed, run by Astria Therapeutics. The registered enrollment target is 29 participants, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05695248, a Phase 1 study of Hereditary Angioedema, has completed, sponsored by Astria Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.
Primary Outcome
An adverse event was any untoward medical occurrence in a clinical investigation participant who was administered a pharmaceutical product that did not necessarily have a causal relationship with the treatment. A treatment-emergent adverse event was defined as any adverse event with an onset at the time of or following the start of treatment with study drug, or medical conditions present before the start of treatment that increased in severity or relationship at the time of or following the star
Conditions Studied
Interventions
- DRUG STAR-0215
Study Locations (20)
Other
- Diagnostical Consultative Center Convex Ltd. - Sofia
- Institute of Clinical Immunology/Allergology, Faculty Hospital - Hradec Králové
- Charité Universitätsmedizin Berlin - Berlin
- Addenbrooke's Hospital - Cambridge
- St. James's Hospital - Leeds
California
- UC San Diego US HAEA Angioedema Center - San Diego
- Raffi Tachdjian MD, Inc - Santa Monica
- Allergy & Asthma Clinical Research - Walnut Creek
Arkansas
- Allergy & Asthma Clinic of Northwest Arkansas - Bentonville
- Acuro Research, Inc. - Little Rock
Alabama
- Allervie Clinical Research - Birmingham
Arizona
- Medical Research of Arizona a Division of Allergy, Asthma & Immunology Associates, LTD. - Scottsdale
Maryland
- Institute for Asthma and Allergy, PC - Chevy Chase
Massachusetts
- Massachusetts General Hospital - Boston
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-02-21 |
| Est. Completion | 2025-03-13 |
| Phase | Phase 1 |
What the finished NCT05695248 record still lists
NCT05695248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 74-participant average among 14 other Hereditary Angioedema trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Hereditary Angioedema appearing as the primary indexed condition, and to 1 intervention - of which STAR-0215 is the first listed.
NCT05695248 names 20 study sites across 13 states, led by Other, California, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05695248 about?
NCT05695248 is a clinical study titled "A Study of STAR-0215 in Participants With Hereditary Angioedema". The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this...
What is the current status of trial NCT05695248?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-02-21. Estimated completion is 2025-03-13.
What conditions does trial NCT05695248 study?
This clinical trial studies the following conditions: Hereditary Angioedema.
What interventions are being tested in trial NCT05695248?
The interventions under investigation include: STAR-0215 (DRUG).
Who is sponsoring clinical trial NCT05695248?
This trial is sponsored by Astria Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05695248 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hereditary Angioedema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05695248's enrollment target sits among peer trials
29 12th of 14 higher than 3 of 14 other Hereditary Angioedema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hereditary Angioedema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 1
-
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
RECRUITING · Phase 3
-
Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab
RECRUITING · Phase 4
-
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
-
A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI